

## 中心复合设计-效应面法优化阿魏酸哌嗪缓释片处方

李颖,王悦,邹梅娟,薛晓柏,程刚

沈阳药科大学药学院, 沈阳 110016

收稿日期 2009-3-26 修回日期 2009-6-30 网络版发布日期 2009-7-30 接受日期 2009-4-26

### 摘要

目的 制备阿魏酸哌嗪缓释片。方法 以羟丙甲纤维素(HPMC)联合羧甲基纤维素钠(CMC-Na)为骨架材料制备阿魏酸哌嗪缓释片,并对影响药物释放的因素进行考察。在此基础上运用中心复合设计-效应面法(central composite design-response surface methodology, CCD-RSM)对方剂进行优化。结果 HPMC K15M及CMC-Na用量是影响药物释放的主要因素,当HPMC K15M与CMC-Na各占片质量分数的20.5%和18.6%时所得缓释片各时间点累计释放率接近合格标准,即25%(2 h)、60%(6 h)、90%(12 h)。结论 HPMC K15M与CMC-Na以一定比例联合使用可以抑制水溶性药物的前期突释,优化处方制备的阿魏酸哌嗪缓释片体外累积释放度符合要求,拟合方程预测性良好。

关键词 [药剂学](#) [缓释片](#) [中心复合设计-效应面优化法](#) [阿魏酸哌嗪](#) [羟丙甲纤维素](#) [羧甲基纤维素钠](#)

分类号 [R94](#)

## Formulation optimization of piperazine ferulate sustained-release tablets by central composite design-response surface methodology

LI Ying, Wang Yue, ZOU Mei-juan, Xue Xiao-bai, CHENG Gang

School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

### Abstract

Objective To prepare piperazine ferulate (PF) sustained-release tablets. Methods The PF sustained-release tablets were prepared by employing the mixture of HPMC K15M and CMC-Na as the basic matrix materials. Factors that affected drug release were investigated. Thereafter, a central composite design-response surface methodology (CCD-RSM) was applied to optimize the formulation of the PF sustained-release tablets. Results The content of HPMC K15M and CMC-Na were the main factors that affected the drug release. The optimized formulation contained 20.5% of HPMC K15M and 18.6% of CMC-Na of the total weight and the accumulative release percentages at 2 h, 6 h, 12 h were consistent with the criterion, that is 25%、60%、90% ,respectively. Conclusions The initial burst release of water-soluble drugs from matrix sustained-release tablets could be restrained by using HPMC combined with a certain proportion of CMC-Na. The optimized PF sustained-release tablets have an ideal cumulative release profile and the fitting equation has a good predictability.

Key words [pharmaceutics](#) [sustained-release tablet](#) [central composite design-response surface methodology](#) [piperazine ferulate](#) [HPMC](#) [CMC-Na](#)

DOI :

通讯作者 程刚 [chenggang63@hotmail.com](mailto:chenggang63@hotmail.com)

作者个人主页 李颖;王悦;邹梅娟;薛晓柏;程刚

### 扩展功能

#### 本文信息

- ▶ [Supporting info](#)
- ▶ [PDF \(291KB\)](#)
- ▶ [\[HTML全文\]\(0KB\)](#)
- ▶ [参考文献\[PDF\]](#)
- ▶ [参考文献](#)

#### 服务与反馈

- ▶ [把本文推荐给朋友](#)
- ▶ [加入我的书架](#)
- ▶ [加入引用管理器](#)
- ▶ [复制索引](#)
- ▶ [Email Alert](#)

#### 相关信息

- ▶ [本刊中 包含“药剂学”的 相关文章](#)
- ▶ 本文作者相关文章

- [李颖](#)
- [王悦](#)
- [邹梅娟](#)
- [薛晓柏](#)
- [程刚](#)